HARBIN, China, April 19 /Xinhua-PRNewswire/ -- China Sky One Medical, Inc. (OTC Bulletin Board: CSKI), one of the leading producers and distributors for external-Chinese medicine in China, has announced that its Research & Development department has discovered a breakthrough method to lower the manufacturing cost of the Slim Patch by 37% and increase the effectiveness of the product by approximately 15%.
"The Slim Patch is safe, effective and extremely popular among consumers," stated Dr. Liu Yan-Qing, Chief Executive Officer and President of China Sky One Medical, Inc. "Obesity is a major problem worldwide. The Slim Patch product had a 65% effectiveness rate, which is now up to approximately 80%, which we believe is high compared to other weight loss products worldwide."
The Slim Patch contains rare extracts naturally found in Chinese herbal plants. These ingredients are highly permeable and are easily absorbed by the skin to lower fat deposits. The patch has been proven to reduce body weight quickly, safely and naturally. The Company has decreased the manufacturing cost of the Slim Patch by using a new, less expensive and more effective trans-dermal component. This component can enhance the skin's absorption of the herbal ingredients which in turn enhances the efficacy of the Slim Patch.
The Science and Technology Office of Heilongjiang Province invited experts to evaluate CSKI's breakthrough method of lowering the manufacturing cost and improving the effectiveness of the Slim Patch. Experts analyzed test data and conducted spot testing on both animals and humans, and concluded that the method was effective.
Takasima has commenced its efforts to market CSKI's Slim Patch product line in Malaysia under a strategic marketing agreement. The Slim Patch is a weight loss product that is currently sold in China under the "Tian Di Ren" brand. The Slim Patch is being repackaged and sold in Malaysia under the "Takasima" brand name. CSKI Management anticipates that efficacy improved slim patch can promote patch sales of Takasima and speed up his introduction of other patches such as reduce waistline patch, hypertension patch.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, American California Pharmaceutical Group, Inc. ("ACPG"), Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Kangxi Medical Care Product Factory ("Kangxi"), and Harbin First Bio-Engineering Company Limited ("First"), the Company's principal revenue source is the manufacture and sale of
over-the-counter pharmaceutical products.
ACPG, a wholly-owned subsidiary of the Company, operates as a holding company for the other subsidiaries. TDR's principal business is the manufacture and sale of branded nutritional supplements and over-the-counter plant and herb-based medicinal products. Its manufacturing facilities are in the City of Harbin, Heilongjiang Province. It has evolved into an integrated manufacturer, marketer, and distributor of external use natural Chinese medicinal products sold primarily to and through domestic pharmaceutical chain stores in China with its subsidiaries, Kangxi and First. Kangxi's principal business activity is to manufacture and sell branded external use Chinese medicine and other natural products under the registered trademark "Kangxi." It has 6 product lines: spray, ointment, powder, patch, cream, and miscellaneous health and beauty products. It has become one of the leading external use Chinese medicine factories with a full range of product lines and development capacity. First's principal business activity is to research and develop the use of natural medicinal plants and biological technology products such as New Endothelin-1. First is one of the first companies in Heilongjiang Province conducting research and development of high technology biological products. Its facility is now under final inspection by the Chinese State Food and Drug Administration ("SFDA") for the qualification as a certified GMP production facility. On July 31, 2006, Kangxi merged with First, with Kangxi's existing business activities continuing under First. http://www.skyonemedical.com
Certain of the statements made herein constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time
For more information, please contact:
Alvin Pan
Sinavest Corporate Relations
Tel: +1-213-225-6226
